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1  | INTRODUC TION
Lymph node metastasis is a critical factor affecting the progno-
sis of patients with head and neck cancer and breast cancer. The 
classical theory proposes that lymph node metastasis occurs pro-
gressively from the upstream section to the downstream section 
of the lymphatic network, so that tumor cells eventually enter 
the blood circulation and produce distant metastases such as 
pulmonary metastasis.1 However, because only 2- 3 lymph nodes 
contain metastases in many cases of distant metastasis, the clas-
sical lymph node metastasis theory cannot easily explain the 
mechanism by which distant metastases are formed.2-4 Indeed, 
only a few cases of metastatic lesions in lymph nodes have been 
reported, but it has been assumed that lymph node metastasis 
plays an important role in the formation of distant metastasis.5-7 
To elucidate the processes leading from lymph node metastasis to 
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Lymph	node	(LN)	dissection	is	a	crucial	procedure	for	cancer	staging,	diagnosis	and	
treatment, and for predicting patient survival. Activation of lung metastatic lesions 
after	LN	dissection	has	been	described	for	head	and	neck	cancer	and	breast	cancer.	
Preclinical	studies	have	reported	that	dissection	of	a	tumor-	bearing	LN	is	involved	in	
the activation and rapid growth of latent tumor metastases in distant organs, but it is 
also	 important	 to	understand	how	normal	 (non-	tumor-	bearing)	LN	 resection	 influ-
ences secondary cancer formation. Here, we describe how the resection of tumor- 
bearing	and	non-	tumor-	bearing	LN	affects	distant	metastases	in	MXH10/Mo-	lpr/lpr 
mice. Tumor cells were administered intravenously and/or intranodally into the right 
subiliac	 lymph	node	(SiLN)	to	create	a	mouse	model	of	 lung	metastasis.	Luciferase	
imaging revealed that tumor cells in the lung were activated after resection of the 
SiLN,	 irrespective	 of	whether	 it	 contained	 tumor	 cells.	No	 luciferase	 activity	was	
detected	in	the	lungs	of	mice	that	did	not	undergo	LN	resection	(excluding	the	intra-
venous	inoculation	group).	Our	results	indicate	that	resection	of	an	LN	can	activate	
distant	metastases	regardless	of	whether	the	LN	contains	tumor	cells.	Hence,	lung	
metastatic	lesions	are	suppressed	while	metastatic	LN	are	present	but	activated	after	
LN	resection.	If	this	phenomenon	occurs	in	patients	with	cancer,	it	is	likely	that	lung	
metastatic	 lesions	may	be	activated	by	elective	LN	dissection	 in	clinical	N0	cases.	
The development of minimally invasive cancer therapy without surgery would help to 
minimize	the	risk	of	activation	of	distant	metastatic	lesions	by	LN	resection.
K E Y W O R D S
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the formation of distant metastasis, our previous study examined 
the communication between the lymphatic network and blood 
circulation in a mouse model of lymph node metastasis in which 
the lymph nodes are of equivalent size to those of humans.8 We 
found numerous blood vessel branches that penetrated the lymph 
node capsule and communicated with blood vessels on the lymph 
node surface.8,9
Because lymph node metastasis results from the proliferation 
of tumor cells that have invaded into the marginal sinus from the 
afferent lymphatic vessels, it is possible that these tumor cells in-
vade the blood vessels penetrating the lymph node capsule and 
enter the blood circulation to reach distant organs, even during 
the early stages of lymph node metastasis. Our previous stud-
ies revealed that tumor cells migrated to the lungs in a relatively 
short period of time after their inoculation into a mouse lymph 
node.10-12 Therefore, we proposed a new concept of lymph node- 
mediated hematogenous metastasis and have been working to 
clarify the mechanisms driving the onset of distant metastasis.9,10 
Papers published recently have supported the theory that lymph 
node vessels provide exit routes for metastatic tumor cells to the 
systemic circulation.13,14 From another point of view, it has been 
shown in clinical studies that tumor cells attached to lung blood 
vessels are not activated for a considerable period of time, but 
these dormant tumor cells can be activated by surgical interven-
tion, such as lymph node dissection.15,16 In preliminary studies, we 
have created a mouse model in which dormant tumor cells in lung 
metastatic lesions are activated after lymph node dissection.10-12 
In this model, the lung metastases were activated after excision of 
the lymph node into which the tumor cells had been inoculated. 
Because lymph node dissection is still considered to be the most 
effective treatment for lymph node metastasis, it is important to 
elucidate the mechanisms by which lymph node dissection acti-
vates distant metastatic lesions. In fact, if lymph node resection 
is confirmed to activate distant metastases in patients, it may be 
necessary to change the standard treatment regime for lymph 
node metastasis. In the present study, we have used a mouse 
model developed by us to further explore how lymph node resec-
tion might activate lung metastases.
2  | MATERIAL S AND METHODS
2.1 | Ethics
The Institutional Animal Care and Use Committee of Tohoku 
University approved all the in vivo studies.
2.2 | Mice
MXH10/Mo-	lpr/lpr	 (MXH10/Mo/lpr)	 mice17 were bred at the 
Institute for Animal Experimentation, Graduate School of Medicine, 
Tohoku University, Japan. Sixty- six female and male mice (aged 
12-	16	weeks)	were	used	in	this	study,	with	no	more	than	4	animals	
housed per cage.
2.3 | Cancer cells
Malignant fibrous histiocytoma- like KM- Luc/GFP cells,18 stably ex-
pressing	a	fusion	of	the	luciferase	(Luc)	and	enhanced	green	fluores-
cent	protein	(EGFP)	genes,	were	used.	On	the	inoculation	day,	cells	
were shown to test negative for Mycoplasma using a commercial kit 
(Lonza	Rockland,	Rockland,	ME,	USA).
2.4 | Induction of experimental tumor metastasis
The experimental procedures were performed under general anes-
thesia with 2.5% isoflurane in oxygen, and great efforts were made to 
minimize animal suffering, as previously reported.10-12 The time of in-
oculation	was	defined	as	0	hour.	A	60	μL volume of KM- Luc/GFP cells 
suspended in PBS (1.0 × 106	cells/mL)	 was	 inoculated	 intravenously	
into the tail vein of the mouse. Intranodal inoculation of cells into the 
right	subiliac	lymph	node	(SiLN)	was	achieved	by	incision	of	the	overly-
ing	skin	and	injection	of	60	μL	of	KM-	Luc/GFP	cells	(vide	supra)	with	
a 27- G injection needle. The needle was maintained in the same posi-
tion	for	1	min	to	prevent	tumor	cells	leaking	from	the	SiLN	after	its	re-
moval.	The	exposed	SiLN	was	thoroughly	irrigated	with	20	mL	of	sterile	
normal saline, and excess fluid was aspirated (M- 20 aspirator; Tokyo 
M.I.	Company,	Tokyo,	Japan).	Wounds	were	closed	with	5-	0	polyam-
ide	 interrupted	 sutures	 (Neoblade	N;	Alfresa	Pharma,	Osaka,	 Japan).	
Accurate intranodal inoculation of KM- Luc/GFP cells and the occur-
rence of metastasis were confirmed when luciferase activity exceeded 
4 × 104	photons/s.	The	mice	were	divided	into	7	groups	(a-	g;	vide	infra)	
according	to	the	inoculation	and	resection	methods	(Figure	1A),	and	the	
f	and	g	groups	were	each	further	divided	into	3	subgroups	(Figure	1B).	
Thus,	there	were	11	groups	in	total	with	6	mice	per	group	(Figure	1B).	
No	 active	 randomization	was	 applied	 to	 experimental	 groups	 before	
the tumor cell inoculation. The groups were as follows:
(a)	 RIN	(intranodal	inoculation	into	the	right	SiLN)	group	(n = 6),	used	
as a control. Tumor cells would enter both the proper axillary 
lymph	node	(PALN)	via	the	afferent	lymphatic	vessel	and	the	sys-
temic circulation via the thoracoepigastric vein.
(b)	 IV	 (intravenous	 inoculation)	 group	 (n = 6),	 which	 provided	 the	
tumor cells with a hematogenous route to the lungs. In this 
group, tumor cells were administered intravenously but were 
not inoculated directly into a lymph node. This method has been 
widely used to induce metastasis in the lungs.
(c)	 IV+RIN	(intravenous	inoculation	and	intranodal	inoculation	into	
the	right	SiLN)	group	(n = 6).
(d)	 IV+RIN+RS	 (intravenous	 inoculation	 and	 intranodal	 inoculation	
into	the	right	SiLN	with	sham	surgery	in	the	region	of	the	right	
SiLN)	group,	which	was	used	 to	examine	 the	effect	of	 surgical	
invasion without lymph node resection. The sham surgery was 
conducted 72 hours after tumor cell inoculation (n = 6).
(e)	 IV+RR	(intravenous	inoculation	with	right	SiLN	resection)	group,	
which was used to investigate the effect of lymph node resection 
during	 the	 formation	of	metastases.	The	 resection	of	 the	SiLN	
was conducted 72 hours after tumor cell inoculation (n = 6).
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(f)	 IV+RIN+LR	 (intravenous	 inoculation	 and	 intranodal	 inoculation	
into	 the	 right	SiLN	with	 resection	of	 the	 left	SiLN),	which	was	
used to observe the effect of resection of a lymph node not con-
taining	 tumor	cells	 (ie,	non-metastatic	 lymph	node).	The	group	
was divided into 3 subgroups (n = 6	per	subgroup)	according	to	
the	 time	 at	 which	 resection	 was	 conducted:	 f1	 (6	hours	 after	
tumor	cell	inoculation),	f2	(72	hours	after	tumor	cell	inoculation)	
and	f3	(144	hours	after	tumor	cell	inoculation).
F IGURE  1 Experimental	interventions	and	groups.	A,	The	experimental	interventions	(a)	to	(g)	show	the	KM-	Luc/GFP	cell	inoculation	
methods and resection techniques used in each group. Syringe: tumor cell inoculation site; black- filled scissors: resection site; white- filled 
scissors:	sham	surgery	site.	B,	Interventions	used	in	each	experimental	group	(a)	RIN	(intranodal	inoculation	into	the	right	SiLN)	control	
group	(n	=	6).	Tumor	cells	would	enter	both	the	PALN	via	the	afferent	lymphatic	vessel	and	the	systemic	circulation	via	the	thoracoepigastric	
vein.	b,	IV	(intravenous	inoculation)	group	(n = 6),	which	provides	a	hematogenous	route	to	the	lung.	This	method	has	been	used	widely	
to	induce	metastasis	in	the	lung.	c,	IV+RIN	(intravenous	inoculation	and	intranodal	inoculation	into	the	right	SiLN)	group.	d,	IV+RIN+RS	
(intravenous	inoculation	and	intranodal	inoculation	into	the	right	SiLN	with	sham	surgery	in	the	region	of	the	right	SiLN)	group	(n = 6),	
which was used to examine the effects of surgical invasion without lymph node resection. The sham surgery was conducted 72 hours after 
tumor	cell	inoculation.	e,	IV+RR	(intravenous	inoculation	with	right	SiLN	resection)	group	(n = 6),	which	was	used	to	investigate	the	effect	
of	lymph	node	resection	during	metastasis	formation.	The	resection	of	the	SiLN	was	conducted	72	hours	after	tumor	cell	inoculation.	f,	
IV+RIN+LR	(intravenous	inoculation	and	intranodal	inoculation	into	the	right	SiLN	with	left	SiLN	resection),	which	was	used	to	observe	the	
effects	of	normal	(ie,	non-	metastatic)	lymph	node	resection.	The	group	was	divided	into	3	subgroups	(n = 6	per	subgroup)	according	to	the	
timing	of	the	resection:	f1	(6	hours	after	tumor	cell	inoculation),	f2	(72	hours	after	tumor	cell	inoculation)	and	f3	(144	hours	after	tumor	cell	
inoculation).	g,	IV+RIN+RR	(intravenous	inoculation	and	intranodal	inoculation	into	the	right	SiLN	with	right	SiLN	resection)	group,	which	was	
used	to	investigate	the	effects	of	metastatic	lymph	node	resection.	The	group	was	divided	into	3	subgroups	(n	=	6	per	subgroup)	according	
to	the	timing	of	the	resection:	g1	(6	hours	after	tumor	cell	inoculation),	g2	(72	hours	after	tumor	cell	inoculation)	and	g3	(144	hours	after	
tumor	cell	inoculation).	PALN,	proper	axillary	lymph	node
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(g)	 IV+RIN+RR	 (intravenous	 inoculation	and	 intranodal	 inoculation	
into	the	right	SiLN	with	resection	of	the	right	SiLN)	group,	which	
was used to investigate the effect of resection of a metastatic 
lymph node. The group was divided into 3 subgroups (n = 6	per	
subgroup)	 according	 to	 the	 time	 at	 which	 resection	 was	 con-
ducted:	 g1	 (6	hours	 after	 tumor	 cell	 inoculation),	 g2	 (72	hours	
after	tumor	cell	 inoculation)	and	g3	(144	hours	after	tumor	cell	
inoculation).
2.5 | Detection of metastasis in the proper axillary 
lymph node
Metastasis	to	the	PALN	was	assessed	using	an	 in	vivo	biolumines-
cence	 imaging	 system	 (IVIS;	 Xenogen,	 Alameda,	 CA,	 USA)18,19 at 
6,	 72,	 144	 and	 216	hours	 post-	inoculation	 of	 tumor	 cells	 (n = 66).	
Each mouse was anesthetized with 2.5% isoflurane in oxygen, and 
15	mg/kg	 luciferin	 (Promega,	Madison,	WI,	 USA)	was	 injected	 in-
traperitoneally. At 10 minutes after the luciferin injection, biolu-
minescence	 images	 were	 captured	 for	 30	seconds	 using	 the	 IVIS.	
Induction of metastasis was considered to have occurred if the lu-
ciferase	intensity	in	the	PALN	was	more	than	the	background	level	
(4 × 104	photons/s).	 In	 a	minority	of	mice,	metastasis	 to	 the	PALN	
failed because of tumor cell blockage of the lymphatic vessels.
2.6 | Induction of metastasis in the lungs after 
resection of the right subiliac lymph node
The experimental procedures were conducted as previously 
reported.10-12 Briefly, on the indicated days after inoculation, mice 
were placed in a supine position on a heated stage and anesthetized by 
inhalation of 2.5% isoflurane in oxygen. After depilation and skin dis-
infection, a minimally invasive approach was used for skin incision and 
exposure and extirpation of the tumor- bearing or non- tumor- bearing 
SiLN.	The	tumor-	bearing	or	non-	tumor-	bearing	SiLN	was	carefully	re-
moved with minimal disruption to the surrounding area, and a bipolar 
coagulator	(Erbotom	VI050C;	ERBE	Elektromedizin	GmbH,	Tübingen,	
Germany)	 and	 surgical	microscope	 (Leica	M80;	Leica	Microsystems	
GmbH,	Wetzlar,	Germany)	were	used	to	facilitate	the	resection	pro-
cess. The surgical area was thoroughly washed with 20 mL of sterile 
saline	(37°C)	to	remove	any	tumor	cells	that	had	leaked	from	the	SiLN.	
The skin wound was closed with 5- 0 polyamide interrupted sutures. 
The entire resection procedure was accomplished within 10 minutes. 
Survival of the mice was monitored, and the experiment was contin-
ued according to the protocol. In mice inoculated with tumor cells into 
the	SiLN,	the	IVIS	was	used	after	surgery	to	determine	whether	the	
tumor-	bearing	SiLN	had	been	completely	resected	and	whether	me-
tastasis had occurred in the lungs.
2.7 | Detection of metastasis in the lung
Metastasis	 to	 the	 lungs	 was	 assessed	 using	 the	 IVIS18,19	 at	 6,	 72,	
144	 and	 216	hours	 post-	inoculation,	 in	 the	 presence	 and	 absence	
of	 the	 SiLN	 (n = 66).	 Luciferin	 (15	mg/kg;	 Promega)	 was	 injected	
intraperitoneally into each mouse. Bioluminescence imaging was 
performed for 30 seconds, 10 minutes after the luciferin injec-
tion. Induction of metastasis was considered to have occurred if 
the luciferase intensity was more than the background level 
(4 × 104	photons/s).	Although	metastasis	in	the	lung	was	not	detected	
by in vivo bioluminescence imaging in some mice, it was subsequently 
confirmed by ex vivo bioluminescence imaging in these mice.
2.8 | Ex vivo analysis
Mice from all 11 experimental groups were humanely euthanized 
under	the	inhalation	of	2.5%	isoflurane	in	oxygen	at	216	hours	post-	
inoculation,	and	the	lungs,	PALN,	spleen	and	liver	were	excised.	Ex	
vivo bioluminescence imaging of the excised organs was performed 
immediately after the in vivo analyses for each mouse.
2.9 | Adverse effects
Daily observations were made of food and water consumption, 
effects of anesthesia, postoperative complications and stool tests. 
Significant weight loss was considered to be >10% of body weight.
2.10 | Histological analysis
The excised organs were fixed in 10% formaldehyde for 4 days at 4°C, 
dehydrated and embedded in paraffin. Specimens were serially sectioned 
(2 μm)	and	stained	with	Elastica-	Masson	(EM)	or	H&E	or	immunostained	
for	 CD31	 or	 Ki67.	 Tumor	 cell	 proliferation	was	 evaluated	 using	 stain-
ing	 for	Ki67.	The	Ki67	 index	 in	 the	 lung	was	quantified	using	 Image	J	
(Bethesda,	Maryland,	USA).20 The hotspot method was used to calculate 
the CD31- positive area in the lung. Four hotspot fields containing the 
highest amount of CD31- positive staining were selected under low mag-
nification	(×10	or	×20),	and	the	positively	staining	area	was	calculated	as	
a percentage of the total area. Total tumor area in the lung was analyzed 
using	cellSens	1.8.1	software	(Olympus,	Tokyo,	Japan)	to	obtain	the	aver-
age diameter of the metastatic foci.
2.11 | Statistical analysis
Statistical significance was determined using one- way analyses of 
variance	 (ANOVA)	Kruskal-	Wallis	 test,	unless	otherwise	 indicated.	A	
P-	value	≤.5	was	considered	to	be	statistically	significant.	All	measure-
ments are presented as the mean ± SEM. Statistical analyses were car-
ried	out	using	Excel	2016	(Microsoft,	Redmond,	WA,	USA)	and	Prism	
7	(GraphPad	Software,	La	Jolla,	CA,	USA).
3  | RESULTS
3.1 | Detection of metastasis in the lung and proper 
axillary lymph node
Figure 2 shows representative in vivo and ex vivo bioluminescence 
images, and Figure S1A and B show ex vivo luciferase activity in the 
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F IGURE  2 Representative in vivo bioluminescence images of mice and ex vivo bioluminescence images of the lungs and proper axillary 
lymph	node	(PALN).	The	lungs	and	PALN	were	harvested	at	216	hours	post-	inoculation	in	all	groups	(n = 6	per	group).	a,	RIN	group:	
intranodal	inoculation	of	the	right	SiLN	without	resection.	b,	IV	group:	intravenous	inoculation	through	the	tail	vein.	c,	IV+RIN	group:	
intravenous	inoculation	through	the	tail	vein	and	intranodal	inoculation	of	the	right	SiLN	without	resection.	d,	IV+RIN+RS-	72	hours	group:	
intravenous	inoculation	through	the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	with	sham	surgery	performed	in	the	region	of	
the	(tumor-	bearing)	right	SiLN	at	72	hours	post-	inoculation.	e,	IV+RR-	72	hours	group:	intravenous	inoculation	through	the	tail	vein	with	
resection	of	the	normal	(ie,	non-	metastatic)	right	SiLN	at	72	hours	post-	inoculation.	f1,	IV+RIN+LR-	6	hours	group:	intravenous	inoculation	
through	the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	with	resection	of	the	non-	tumor-	bearing	left	SiLN	at	6	hours	post-	
inoculation.	f2,	IV+RIN+LR-	72	hours	group:	intravenous	inoculation	through	the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	
with	resection	of	the	non-	tumor-	bearing	left	SiLN	at	72	hours	post-	inoculation.	f3,	IV+RIN+LR-	144	hours	group:	intravenous	inoculation	
through	the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	with	resection	of	the	non-	tumor-	bearing	left	SiLN	at	144	hours	post-	
inoculation.	g1,	IV+RIN+RR-	6	hours	group:	intravenous	inoculation	through	the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	with	
resection	of	the	tumor-	bearing	right	SiLN	at	6	hours	post-	inoculation.	g2,	IV+RIN+RR-	72	hours	group:	intravenous	inoculation	through	
the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	with	resection	of	the	tumor-	bearing	right	SiLN	at	72	hours	post-	inoculation.	g3,	
IV+RIN+RR-	144	hours	group:	intravenous	inoculation	through	the	tail	vein	and	intranodal	inoculation	into	the	right	SiLN	with	resection	of	
the	tumor-	bearing	right	SiLN	at	144	hours	post-	inoculation.	No	ex	vivo	luciferase	activity	was	detected	in	the	lung	in	the	non-	resection	
groups,	with	the	exception	of	the	IV	group.	Tumor	cells	in	the	lung	were	activated	after	resection	of	the	SiLN	in	the	resection	groups,	
excluding	the	IV+RR	group.	Tumor	cells	metastasized	by	the	hematogenous	route	after	inoculation	into	the	tail	vein	in	the	IV	and	IV+RR	
groups; therefore, induction of lung metastasis was independent of lymph node removal. Ex vivo luciferase activity in the lung was highest 
in	the	IV+RR-	72	hours	and	the	IV+RIN+RR6	hours	groups.	In	the	IV+RIN+LR	groups,	luciferase	activity	in	the	lung	was	highest	when	the	
resection	was	performed	early	(6	hours)	and	lowest	when	it	was	performed	late	(144	hours).	Metastasis	in	the	PALN	was	detected	in	the	RIN	
and	IV+RIN+RR	groups.	Metastasis	in	the	PALN	was	not	detected	in	the	IV,	IV+RR,	IV+RIN	or	IV+RIN+RS	groups
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lung	and	PALN,	respectively.	After	intranodal	inoculation	into	the	right 
SiLN	(ie,	RIN	group),	tumor	cells	migrated	to	the	PALN	via	the	lym-
phatic vessels and to the lung through the systemic blood circulation 
via	the	thoracoepigastric	vein	(Figure	1Aa).	The	incidence	of	metas-
tasis	in	the	lung	and	PALN	was	17%	and	50%,	respectively	(Table	1,	
Figure	S1A	and	B).	In	the	IV	group	(Figure	1Ab),	in	which	tumor	cells	
were directly inoculated into the tail vein, the incidence of metastasis 
in	the	lung	and	PALN	was	100%	and	0%,	respectively	(Table	1,	Figure	
S1A	and	B).
In	the	IV+RIN	group	(Figure	1Ac),	the	incidence	of	metastasis	in	
the	lung	(17%)	was	lower	than	that	in	the	IV	group,	and	the	incidence	
of	metastasis	in	the	PALN	(17%)	was	lower	than	that	in	the	RIN	group	
(Table	1,	Figure	S1A	and	B).	The	incidence	of	metastasis	in	the	lung	
in	the	IV+RIN+RS-	72	hours	group	(Figure	1Ad)	was	also	lower	than	
that	in	the	IV	group	(33%	vs	100%).
In	the	groups	in	which	normal	(non-	metastatic)	lymph	nodes	were	re-
sected,	ie,	the	IV+RR-	72	hours,	IV+RIN+LR-	6	hours,	IV+RIN+LR-	72	hours	
and	IV+RIN+LR-	144	hours	groups	(Figure	1Ae,f),	the	incidence	of	metas-
tasis in the lung was increased to 100%, 83%, 100% and 83%, respectively, 
and	the	incidence	of	metastasis	in	the	PALN	was	suppressed	to	0%,	0%,	
17%	and	0%,	respectively	 (Table	1,	Figure	S1A	and	B).	The	 incidence	of	
lung metastasis in the above groups was dependent on the timing of the 
lymph node resection. In the groups in which tumor- bearing lymph nodes 
were	 resected,	 ie,	 the	 IV+RIN+RR-	6	hours,	 IV+RIN+RR-	72	hours	 and	
IV+RIN+RR-	144	hours	 groups	 (Figure	1Ag),	 the	 incidence	 of	metastasis	
in the lung increased to 83%, 100% and 100%, respectively, and the in-
cidence	of	metastasis	in	the	PALN	decreased	to	50%,	50%	and	33%,	re-
spectively	(Table	1,	Figure	S1A	and	B).	The	incidence	of	metastasis	in	the	
lung	and	PALN	in	the	IV+RIN+RR	groups	was	dependent	on	the	timing	
of	the	resection	of	the	tumor-	bearing	lymph	node.	No	statistically	signif-
icant differences were observed in the activation of the lung metastasis 
between	the	groups.	No	statistically	significant	differences	were	found	for	
metastasis	in	the	PALN	between	the	groups.	These	results	suggest	that	re-
section of a lymph node increased the incidence of metastasis in the lung, 
irrespective of whether the lymph node contained tumor cells. In addition, 
resection	of	a	tumor-	bearing	lymph	node	(ie,	a	SiLN	inoculated	with	tumor	
cells)	induced	metastasis	to	the	downstream	lymph	node	(PALN).	The	in-
cidence of metastasis in the lung was dependent on the timing of lymph 
node resection regardless of whether tumor cells were absent or present. 
The	incidence	of	metastasis	in	the	PALN	was	independent	of	normal	lymph	
node resection but dependent on the time at which a tumor- bearing lymph 
node was resected. It should be noted that significant weight loss was not 
observed	during	these	experiments	(Figure	S1C).
3.2 | Histological analysis
Figure 3 shows representative lung sections stained with H&E or EM 
or	 immunostained	 for	 Ki67.	 Tumor	 cells	were	 found	 in	 the	 pulmo-
nary	arteriol	of	the	 IV,	 IV+RR-	72	hours,	 IV+RIN+LR	and	IV+RIN+RR	
groups	 (Figure	3b1,e1-	k1).	 The	 boxes	 in	 the	 H&E-	stained	 sections	
highlight	 the	 regions	 shown	 for	 Ki67	 immunostaining	 (Figure	3a2-	
k2).	 No	 tumor	 foci	 in	 the	 lung	 were	 found	 in	 the	 RIN,	 IV+RIN	 or	
IV+RIN+RS-	72	hours	groups.	Several	Ki67	positive	cells	were	found	
in the tumor mass of dissection groups. Figure 4 shows the aver-
age	 diameter	 of	 the	 metastatic	 foci,	 total	 tumor	 area,	 Ki67	 index	
and CD31- positive area in the lung. The maximal average diameter 
of the metastatic foci (137.5 ± 21.7 μm)	was	detected	in	the	lungs	of	
the	IV+RR-	72	hours	group,	and	the	smallest	average	diameter	of	the	
TABLE  1 Conditions and subsequent results
Group n
Incidence of metastasisa
Average diameter of metastatic 
foci in the lung (μm)
Lung PALN
Metastasis (+)b Percentage (%) Metastasis (+) Percentage (%)
a RIN 6 1 17 3 50 19.3 ± 3.7
b IV 6 6 100 0 0 64.0	±	13.6
c IV+RIN 6 1 17 1 17 5.5 ± 2.4
d IV+RIN+RS-	72	h 6 2 33 0 0 14.0 ± 3.3
e IV+RR-	72	h 6 6 100 0 0 137.5 ± 21.7
f
 1 IV+RIN+LR-	6	h 6 5 83 0 0 71.4 ± 18.8
 2 IV+RIN+LR-	72	h 6 6 100 1 17 65.9	±	17.5
 3 IV+RIN+LR-	144	h 6 5 83 0 0 103.0 ± 24.3
g
 1 IV+RIN+RR-	6	h 6 5 83 3 50 96.9	±	19.0
 2 IV+RIN+RR-	72	h 6 6 100 3 50 90.8 ± 13.8
 3 IV+RIN+RR-	144	h 6 6 100 2 33 121.5 ± 19.2
IV,	intravenous	inoculation	into	the	tail	vein;	IVIS,	in	vivo	bioluminescence	imaging	system;	PALN,	proper	axillary	lymph	node;	RIN,	intranodal	inocula-
tion	into	the	right	SiLN.
aThe	incidence	of	metastasis	was	determined	by	ex	vivo	bioluminescence	in	lung	and	PALN.	
b(+)	means	that	metastasis	was	positive.	
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metastatic foci (5.5 ± 2.4 μm)	was	detected	in	the	lungs	of	the	IV+RIN	
group	(Table	1	and	Figure	4A).	The	average	diameter	of	the	metastatic	
foci	in	the	lungs	of	the	IV+RR-	72	hours	group	was	higher	than	that	of	
the	IV	group.	Statistically	significant	differences	were	found	for	RIN	
vs	IV,	IV+RIN	vs	IV+RR-	72	hours,	IV+RIN	vs	IV+RIN+LR-	6	hours,	and	
IV+RIN+RS-	72	hours	vs	IV+RR-	72	hours.	The	formation	of	metastatic	
foci in the lung was not obviously dependent on whether a normal 
lymph	node	or	tumor-	bearing	lymph	node	was	resected	(Figure	4A).	
However, we found that later resection of the lymph node in the 
IV+RIN+LR	and	 IV+RIN+RR	groups	appeared	 to	be	associated	with	
the formation of larger metastatic foci.
As shown in Figure 4B, the smallest tumor area was found in the 
lungs	of	the	RIN,	IV+RIN	and	IV+RIN+RS	groups,	and	the	tumor	area	
was increased in all the resection groups. The maximal tumor area 
was	found	in	the	IV+RR	and	IV+RIN+RR-	6	hours	groups	(Figure	4B).	
In	 the	 IV+RIN+LR	group,	 the	 total	 tumor	area	appeared	 to	 increase	
as	 the	 timing	 of	 the	 resection	 of	 the	 normal	 SiLN	 was	 delayed	
(Figure	4B).	A	statistically	significant	difference	was	found	for	RIN	vs	
IV+RIN,	RIN	vs	IV+RIN+RS-	72	hours,	IV+RIN	vs	IV+RR-	72	hours,	and	
IV+RIN+RS-	72	hours	vs	IV+RR-	72	hours.
Figure	4C	shows	 the	Ki67	 index	 in	 the	 lung.	Tumor	cell	prolifer-
ation	was	 numerically	 higher	 in	 the	 IV+RR	 group	 than	 in	 the	 other	
experimental groups. A statistically significant difference was found 
for	RIN	vs	 IV+RR-	72	hours,	RIN	vs	 IV+RIN+RR-	6	hours,	 and	RIN	vs	
IV+RIN+RR-	144	hours.
Figure 4D shows the CD31- positive area in the lung (CD31- 
immunostained	sections	are	shown	in	Figure	S2a2-	k2).	No	significant	
differences were detected between groups. However, the minimal 
CD31-	positive	area	was	observed	in	the	IV+RIN+RS	group,	whereas	
the	maximal	CD31-	positive	area	was	detected	 in	the	SiLN	resection	
groups	 (IV+RIN+LR	 and	 IV+RIN+RR).	 Although	 the	 CD31-	positive	
area appeared to increase in the lymph node resection groups, this 
increase was independent of the resection time.
Sections	 of	 the	 PALN	 stained	 with	 H&E	 or	 immunostained	
for	 Ki67	 are	 shown	 in	 Figure	 S2.	Metastasis	was	 detected	 in	 the	
PALN	of	the	RIN,	IV+RIN+RS-	72	hours,	IV+RIN+RR	and	IV+RIN+LR	
F IGURE  3 Histological	analysis	of	the	lung.	a,	RIN,	b,	IV,	c,	IV+RIN,	d,	IV+RIN+RS-	72	hours,	e,	IV+RR-	72	hours,	f1,	IV+RIN+LR-	6	hours,	
f2,	IV+RIN+LR-	72	hours,	f3,	IV+RIN+LR-	144	hours,	g1,	IV+RIN+RR-	6	hours,	g2,	IV+RIN+RR-	72	hours,	g3,	IV+RIN+RR-	144	hours.	A,	C,	D,	
The	lung	structure	was	normal	in	the	RIN,	IV+RIN	and	IV+RIN+RS	groups.	B,	E-	K,	Metastatic	foci	in	the	lung	were	observed	in	the	IV,	IV+RR,	
IV+RIN+LR	and	IV+RIN+RR	groups.	HE	staining:	A-	K,	EM	staining:	a1-	k1,	and	immunostaining	of	Ki67:	a2-	k2.	The	lungs	were	harvested	
at	216	hours	post-	inoculation.	Scale	bar:	50	μm.	Boxes	in	A-	K	outline	the	region	shown	in	a2-	k2.	In	the	IV	and	IV+RR-	72	hours	groups,	
proliferating tumor cells were found in the blood vessels after intravenous inoculation of the tumor cells. Tumor cells in the lung were 
activated	after	resection	of	the	SiLN	in	the	IV+RIN+LR	and	IV+RIN+RR	groups.	Tumor	cell	proliferation	in	the	metastatic	foci	was	higher	in	
the	groups	showing	notable	lung	metastasis	than	in	the	RIN,	IV+RIN	and	IV+RIN+RS	groups.	EM,	Elastica-	Masson
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groups. Histologically, no tumor cells were found in the liver and 
spleen	in	sections	stained	with	H&E	in	all	the	groups	(Figure	S3).
4  | DISCUSSION
Activation of lung metastatic lesions after lymph node resection 
has been reported in clinical studies of head and neck cancer and 
breast cancer.3,21 We have proposed a new concept of lymph node- 
mediated hematogenous metastasis in which tumor cells invade the 
blood vessels of the lymph node capsule and then induce metastasis 
in distant organs during the early stages of lymph node metasta-
sis.10,12 Our previous studies have revealed that tumor cells reach 
the lungs in a relatively short period of time after their inoculation 
into mouse lymph nodes.9,10,12 Although it has been confirmed that 
lung metastatic lesions are activated by resection of lymph nodes 
inoculated with tumor cells, the underlying mechanisms remain 
unknown.10,12 In the present study, we used a mouse model to 
study lung metastasis activation by lymph node resection and ex-
plore which conditions promoted the activation of lung metastases 
(Figure	2).
In	 the	RIN	group,	 in	which	 tumor	cells	were	 inoculated	 into	 the	
SiLN,	lung	metastasis	occurred	infrequently	with	only	small	metastatic	
foci	observed	(Figure	2a	and	Table	1).	In	the	IV	group,	which	received	
an intravenous inoculation of tumor cells, lung metastasis was con-
firmed in all cases with clear evidence of metastatic foci (Figure 2 and 
Table	1).	However,	 in	 the	 IV+RIN	group,	which	was	 inoculated	with	
tumor	 cells	 both	 intravenously	 and	 into	 the	 SiLN,	 lung	 metastasis	
was	 less	 extensive	 than	 that	 in	 the	 IV	 group	 (Figure	2	 and	Table	1).	
Although this finding suggests that the presence of tumor cells in a 
lymph	node	 (ie,	 lymph	node	metastasis)	may	 suppress	 the	develop-
ment and/or progression of lung metastasis, the underlying mecha-
nism is unknown. Engel et al22 report that randomized clinical trials (ie, 
the	highest	level	of	clinical	evidence)	did	not	reveal	a	survival	benefit	
F IGURE  4 Quantification of the histological analyses. A, Average diameter of the metastatic foci in the lung was quantified from 
HE-	stained	sections.	A	statistically	significant	difference	was	found	between	the	RIN	and	IV	groups	(Kruskal-	Wallis	test:	*P < .05,	RIN	
vs	IV),	IV+RIN	and	IV+RR-	72	hours	groups	(Kruskal-	Wallis	test:	**P < .01,	IV+RIN	vs	IV+RR-	72	hours),	IV+RIN	and	IV+RIN+LR-	6	hours	
groups	(Kruskal-	Wallis	test:	*P < .05,	IV+RIN	vs	IV+RIN+LR-	6	hours),	and	IV+RIN+RS-	72	hours	and	IV+RR-	72	hours	groups	(Kruskal-	Wallis	
test:	*P < .05,	IV+RIN+RS-	72	hours	vs	IV+RR-	72	hours).	Data	are	presented	as	the	mean	±	SEM.	B,	The	total	tumor	area	in	the	lung	was	
quantified	from	HE-	stained	sections.	A	statistically	significant	difference	was	found	between	the	RIN	and	IV+RIN	groups	(Kruskal-	Wallis	
test:	***P < .001,	RIN	vs	IV+RIN),	RIN	and	IV+RIN+RS-	72	hours	groups	(Kruskal-	Wallis	test:	**P < .01,	RIN	vs	IV+RIN+RS-	72	hours),	IV+RIN	
and	IV+RR-	72	hours	groups	(Kruskal-	Wallis	test:	*P < .05,	IV+RIN	vs	IV+RR-	72	hours)	and	IV+RIN+RS-	72	hours	and	IV+RR-	72	hours	
groups	(Kruskal-	Wallis	test:	**P < .01,	IV+RIN+RS-	72	hours	vs	IV+RR-	72	hours).	Data	are	presented	as	the	mean	±	SEM.	C,	Ki67	index	
in	the	lung	was	quantified	from	sections	immunostained	for	Ki67.	There	were	statistically	significant	differences	between	the	RIN	and	
IV+RR-	72	hours	groups	(Kruskal-	Wallis	test:	***P < .001,	RIN	vs	IV+RR-	72	hours),	RIN	and	IV+RIN+RR-	6	hours	(Kruskal-	Wallis	test:	*P < .05, 
RIN	vs	IV+RIN+RR-	6	hours)	and	RIN	and	IV+RIN+RR-	144	hours	groups	(Kruskal-	Wallis	test:	**P < .01,	RIN	vs	IV+RIN+RR-	144	hours).	Data	
are	presented	as	the	mean	±	SEM.	D,	CD31-	positive	area	quantified	from	sections	immunostained	for	CD31.	No	statistically	significant	
differences were detected. Data are presented as the mean ± SEM
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of lymph node dissection. Engel's team have evaluated the prognosis 
associated with a positive lymph node and the growth rate of a pos-
itive lymph node, estimating the time of first and subsequent lymph 
node infiltrations,23,24 and their data support the basic hypothesis that 
a positive lymph node does not metastasize.22,25 In contrast, in our 
study, activation of lung metastasis was not induced by sham surgery 
but was induced by excision of lymph nodes irrespective of whether 
they	 had	 been	 inoculated	 with	 tumor	 cells	 (Figure	2	 and	 Table	1).	
There was no evidence that the period of tumor cell proliferation or 
the size of the metastatic lesion in the lymph node defined the level 
of activation of lung metastasis. To summarize the above findings, 
lung	metastasis	(after	intravenous	inoculation	of	tumor	cells)	was	sup-
pressed to some extent during the period in which a metastatic lymph 
node was present, but tumor cells in the lung arteriols were activated 
by resection of a lymph node irrespective of whether the lymph node 
contained	tumor	cells	(Figures	2	and	3	and	Table	1).
If the same phenomenon were to occur in patients with cancer, 
it is possible that lung metastasis would be activated by elective 
resection	 of	 lymph	 nodes	 in	 clinical	N0	 cases.	 Therefore,	 if	 elec-
tive lymph node dissection activates potential microscopic distant 
metastases, which are not detectable using current diagnostic im-
aging systems, cancer radio- chemotherapy without surgical treat-
ment might be considered a more desirable option in patients with 
N0	disease.	However,	considering	the	adverse	effects	and	the	un-
certainty of the response, it would not be realistic to recommend 
cancer	 radio-	chemotherapy	 without	 surgery	 to	 patients	 with	 N0	
disease.
In earlier studies, we examined the communication between the 
lymphatic network and blood circulation in a mouse model of lymph 
node metastasis.8,9 Interestingly, we observed several blood vessel 
branches that penetrated the lymph node capsule.8,9 In addition, the 
findings indicated that tumor cells invaded from the afferent lymphatic 
vessels into the marginal sinuses of the lymph nodes and infiltrated 
the vessel branches penetrating the lymph node capsule at an early 
stage of tumor cell proliferation.8,9 We have considered previously de-
scribed phenomena that might account for the mechanisms of distant 
metastasis onset and proposed a theory of metastasis termed lymph 
node- mediated hematogenous metastasis.8,9 In the present study, 
tumor cells were inoculated into the lymph node and/or injected intra-
venously into the tail vein, and lung metastasis was confirmed after the 
removal of the lymph node, regardless of whether or not it contained 
tumor cells. Our current understanding is that intravenously and in-
tranodally inoculated tumor cells reach lung blood vessels and remain 
there in an inactive mode. The activation of latent metastatic cells 
after lymph node resection indicates that an immunological response 
had initially prevented the progression of metastasis in the lung and 
that lymph node resection had disrupted this immunological response. 
Thus, latent metastasis in the lung implies that lymph node- mediated 
hematogenous metastasis had occurred. Tumor latency is a stage of 
tumor development that is not associated with clinical symptoms. Two 
mechanisms have been implicated in tumor latency: one involves a 
single disseminated tumor cell undergoing growth arrest and is called 
tumor cell dormancy, and the other involves cell cycle arrest and is 
termed tumor mass dormancy.26-28	The	observation	of	Ki67-	positive	
cells suggests that, in certain niches, dormant cells are activated to 
divide. Additional research is needed to investigate the immune re-
sponses and cell cycle changes that occur after tumor cell inoculation 
and lymph node resection. We do not know which molecules are 
involved in the activation of tumor cells in the lung after resection. 
Recently, we observed that lysine oxidase expression was significantly 
higher in lymph node resection groups than in the control group.12 
These findings are consistent with the results of previous studies,29,30 
suggesting that high lysine oxidase expression in metastatic sites is 
closely associated with tumor cell colonization and metastasis.
One limitation of the present study was that only one cell line (KM- 
Luc/GFP)	 and	mouse	 strain	 (MXH10/Mo/lpr)	were	used.	 Further	 ex-
periments utilizing different cell lines and mouse strains are needed to 
confirm the present results. Another potential limitation was that our 
experimental model of lung metastasis (generated using intravenous or 
intranodal	 injection	of	 tumor	cells)	did	not	 fully	 replicate	 the	process	
of systemic metastasis that occurs in patients with cancer. However, 
the results obtained using this model may still be relevant to cancer 
metastasis in humans. In addition, it will be important to elucidate the 
molecular mechanisms underlying the activation of latent pulmonary 
metastases by the resection of tumor- bearing and tumor- free lymph 
nodes.
Development of a minimally invasive treatment to prevent lymph node- 
mediated hematogenous metastasis is desirable, and we have previously re-
ported	(using	the	same	animal	model)	that	anticancer	drugs	can	be	injected	
into an upstream lymph node to treat micrometastasis in a downstream 
lymph node.31-33 A lymphatic anticancer drug delivery system can remove 
the origin of lymph node- mediated hematogenous metastasis by targeting 
micrometastases in lymph nodes, avoiding surgical intervention and pre-
venting the risk of activation of distant metastatic lesions by lymph node 
resection. Therefore, this novel cancer chemotherapy approach may be a 
promising technique that should be further investigated in future studies.
In conclusion, tumor- bearing or non- tumor- bearing lymph node 
resection/biopsy could be responsible for an increased incidence of 
secondary cancer foci. The resection/biopsy of metastatic lymph 
nodes may increase metastasis via hematogenous and lymphog-
enous pathways if the lymph nodes contain tumor cells. Removal of 
healthy lymph nodes may induce metastases in distant organs if the 
organs contain latent tumor cells. It is important to develop an im-
proved diagnostic method that can diagnose cancer at an early stage 
to help limit its progression. The development of minimally invasive 
cancer therapy without surgical intervention would potentially re-
move the risk of activation of distant metastatic lesions by lymph 
node resection. Thus, intranodal or intralymphatic inoculation of 
de- activated tumor cells may potentially lead to lymphatic system 
vaccination.
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